Form 4: Moderna CFO James Mock Reports Routine Stock Transactions from RSU Vesting

Moderna's Chief Financial Officer, James M. Mock, reported the acquisition of common stock through restricted stock unit conversions and subsequent sales to cover tax obligations on May 27 and May 28, 2025.

Summary

• James M. Mock, Chief Financial Officer of Moderna, Inc. (MRNA), filed a Form 4 detailing changes in his beneficial ownership of company securities.
• On May 27, 2025, Mr. Mock acquired 773 shares of common stock through the conversion of Restricted Stock Units (RSUs) and simultaneously disposed of 374 shares at a price of $26.26 per share to satisfy tax withholding obligations.
• On May 28, 2025, he acquired an additional 328 shares of common stock from RSU conversions and disposed of 159 shares at $26.76 per share for tax withholding purposes.
• Following these reported transactions, Mr. Mock directly beneficially owns 16,191 shares of Moderna common stock.
• He also holds 8,510 Restricted Stock Units from an award where 25% vested on February 27, 2025, with the remainder vesting in twelve equal quarterly installments.
• Additionally, he holds 2,302 Restricted Stock Units from another award where 25% vested on February 28, 2024, with the remainder also vesting in twelve equal quarterly installments.

Sentiment

Score: 6

Explanation: The document reports routine insider transactions related to executive compensation. It is neutral in terms of company performance but indicates ongoing RSU vesting, which is a positive for executive retention and alignment of interests.

Positives

• The transactions primarily involve the vesting and conversion of Restricted Stock Units (RSUs), indicating the fulfillment of long-term incentive compensation for the CFO.
• The acquisition of common stock through RSU conversion increases the CFO's direct ownership in the company, aligning his interests with those of shareholders.

Negatives

• A portion of the acquired shares was immediately sold to cover tax withholding obligations, which is a common practice but reduces the net increase in direct ownership from the RSU vesting.

Future Outlook

This Form 4 filing primarily reports past and current insider transactions related to executive compensation and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook, beyond the stated vesting schedules for the remaining Restricted Stock Units.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, reflecting standard executive compensation practices within the biotechnology and pharmaceutical industries. Equity awards like Restricted Stock Units (RSUs) are a common component of executive pay packages, designed to align management incentives with long-term shareholder value. The sale of shares to cover tax obligations upon vesting is also a typical occurrence in such compensation structures.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a common practice across the biotechnology and pharmaceutical industries, aligning executive incentives with long-term shareholder value, similar to practices at companies like Pfizer, BioNTech, or AstraZeneca.
• The sale of shares to cover tax withholding obligations upon RSU vesting is a standard and expected practice for executives receiving equity compensation, consistent with practices observed at comparable public biopharmaceutical companies.
• The reported beneficial ownership levels for a Chief Financial Officer of a company like Moderna are generally within the expected range for executives at similar-sized public biopharmaceutical companies, reflecting a typical mix of salary and equity-based compensation.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices and a slight net increase in direct insider ownership, which can be viewed positively as it aligns management interests with shareholders. The sales for tax purposes are routine and not indicative of a lack of confidence.
• Employees: The RSU vesting demonstrates the company's ongoing equity compensation programs, which can be a positive for employee retention and motivation within the organization.

Next Steps

• The remaining Restricted Stock Units (8,510 and 2,302 units) will continue to vest in twelve equal quarterly installments as per their respective award schedules.

Key Dates

Recommendation

Keywords

Moderna, MRNA, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Ownership, Executive Compensation, James Mock, CFO, Biotechnology, Pharmaceuticals